CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger...(combination. Talecris continues to focu...)

Date:6/8/2009

combination. Talecris continues to focus on its patient community and customers, and on building and realizing value for its employees and owners. Through the process, we developed an even greater appreciation for CSL's competencies, professionalism and integrity, and we wish Brian and his team well in their future endeavors."

Both parties will fulfill their obligations for termination contained in the merger agreement. As part of the agreement, CSL will pay Talecris a US$75 million break fee, and the plasma supply contract the parties entered into in connection with the merger agreement will remain in effect.

CSL and Talecris remain highly committed to their respective customers and patient communities.

About CSL

Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2008, the company produced revenues of approximately A$3.8 billion. www.csl.com.au

About Talecris

Talecris Biotherapeutics, with revenues of approximately US$1.4 billion in 2008 and headquartered in Research Triangle Park, North Carolina is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, neurology, pulmonology, and hemostasis. www.talecris.com

    CSL Media Contacts:
    Australia
    Dr. Rachel David
    Director, Public Affairs
    Tel: +61 3 9389 1821
    Email: '/>"/>
SOURCE  CSL Limited; Talecris Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 
Related biology technology :

1. Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
2. Boston Scientific Acquires Labcoat Limited
3. Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100
4. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
5. Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
6. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
9. Application for Listing of Shire Limited Ordinary Shares
10. Limited transparency in federal nanotech research may hamper development
11. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement